Tuberculosis — A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)
Citation(s)
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as a Single Adjuvant Amount With Different Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection